The IL-7Rα targeted monoclonal antibody, lusvertikimab, has shown preliminary efficacy against ulcerative colitis (66) and IL7Rα+ T cell acute lymphoblastic leukemia (T-ALL) (67). Here, IL7R is linked to T-cell acute lymphoblastic leukemia.